On the other hand, in vivo data indicate that although virotherapy with free MYXV (i.e., un-armed vMyx-M135KO or armed human TNF expressing vMyx-hTNF recombinant constructs) delays the onset of MM disease, this monotherapy treatment was insufficient to eliminate or control the eventual progression of the disease. Here, TNF is linked to Miyoshi myopathy.